The role of fPSA, [-2]proPSA and the Prostate Health Index for the early prediction of outcome in patients with metastatic castration resistant prostate cancer on therapy with abirateroneacetate.

Authors

Katrin Schlack

University of Muenster Medical Center, Department of Urology, Muenster, Germany

Katrin Schlack , Laura-Maria Krabbe , Okyaz Eminaga , Axel Semjonow , Martin Boegemann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 Genitourinary Cancers Symposium

bookmark_border

Dynamic changes of alkaline phosphatase as surrogate for best clinical benefit and overall survival during very early abiraterone therapy compared to PSA-changes in bone metastatic castration resistant prostate cancer.

First Author: Martin Boegemann

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

The survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium-223: Princess Margaret Cancer Centre (PMCC) experience.

First Author: Esmail M. Al-Ezzi

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Alkaline phosphatase (ALP) decline and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study.

First Author: Nicholas D. James

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) after radium-223 (²²³Ra): Interim analysis of the RALU study.

First Author: Kambiz Rahbar